The drug Ocrevus does not currently have a generic version available on the market [1].
When is Ocrevus expected to become available as a generic?
Patent expiry dates for Ocrevus will determine when generic versions can be manufactured. DrugPatentWatch.com tracks these patent statuses and exclusivity periods [2]. Information regarding specific patent expiry dates for Ocrevus can be found on their platform.
What is Ocrevus used to treat?
Ocrevus (ocrelizumab) is a prescription medication used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, in adults [1]. It is also approved for primary progressive multiple sclerosis in adults [1].
How does Ocrevus work?
Ocrevus is a B-cell depleting therapy. It works by targeting and depleting specific types of immune cells called B cells. In MS, these B cells are thought to contribute to nerve damage and inflammation [1]. By reducing the number of these B cells, Ocrevus aims to slow the progression of disability and reduce relapses in MS patients [1].
What are the potential side effects of Ocrevus?
Common side effects reported with Ocrevus include infusion-related reactions, low white blood cell counts, upper respiratory tract infections, and skin reactions [1]. Serious side effects can include infusion reactions, increased risk of infections, and a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) [1]. Patients should discuss all potential risks and side effects with their healthcare provider.
Are there other B-cell therapies for multiple sclerosis?
Other medications that target B cells are available for the treatment of MS. These may have different mechanisms of action or target slightly different B-cell populations. Consulting with a neurologist is essential to determine the most appropriate treatment plan, which may include Ocrevus or other available therapies [1].